Saro Therapeutics

Saro Therapeutics is a preclinical-stage biotechnology company focused on developing transformative tRNA-based therapies for rare genetic diseases caused by nonsense mutations. The company's primary focus is on cystic fibrosis, specifically targeting the subset of patients with Class I mutations who do not benefit from existing CFTR modulators. Their proprietary platform utilizes suppressor tRNAs to enable the read-through of premature stop codons, thereby restoring the production of full-length, functional proteins. Headquartered in the Boston area, Saro Therapeutics aims to expand its genetic medicine approach to a variety of underserved genetic disorders beyond pulmonology.